Products

ScreenPoint Medical
ScreenPoint Medical
Clinical Decision Support & Reference
ScreenPoint Medical offers Transpara, an AI-powered solution for breast cancer detection and diagnosis in mammography and digital breast tomosynthesis, designed to assist radiologists.
Transpara Density
Screenpoint Medical B.V.
Oncology AI
Transpara Density is an AI-powered software that automates breast density assessment, providing BI-RADS-like and volumetric breast density (VBD) measurements for consistent and compliant reporting in mammography.
Transpara
ScreenPoint Medical B.V.
Clinical Decision Support & Reference
Transpara is an FDA-cleared AI solution by ScreenPoint Medical B.V. that enhances breast cancer detection and optimizes radiologist workflow for 2D and 3D mammography.

See all 3 products →

About ScreenPoint Medical B.V.

ScreenPoint Medical B.V. is a leading “Breast AI Company” dedicated to developing and commercializing AI-powered technology for the entire breast imaging continuum. Their primary goal is to enhance consistency, reduce diagnostic uncertainty, improve the patient experience, and ultimately deliver personalized, precision medicine in breast cancer care. The company translates cutting-edge machine learning research into practical technology accessible to radiologists, aiming to improve screening workflow, decision confidence, and breast cancer risk assessment.

Their flagship product, Transpara®, is an FDA-cleared and CE-marked AI solution designed to assist physicians in interpreting both 2D full-field digital mammography and 3D digital breast tomosynthesis exams. Transpara utilizes deep learning algorithms to identify suspicious calcifications and soft tissue lesions (including densities, masses, architectural distortions, and asymmetries) and assesses their likelihood of malignancy. It is built to integrate seamlessly into existing clinical workflows, working with various PACS systems and imaging technologies, and is currently deployed in healthcare systems across more than 30 countries.

Clinical evidence, including over 55 peer-reviewed studies and three randomized controlled trials, supports Transpara’s ability to improve breast cancer detection rates, reduce radiologist workload, and enhance diagnostic accuracy. The system provides a “second pair of eyes” for radiologists, allowing for earlier detection and more effective, less invasive treatment options.

Focus Areas

AI-driven medical image analysis mammography breast cancer detection early detection decision support breast density assessment breast cancer risk assessment workflow optimization

Business Intelligence

Key InvestorsInsight Partners, Siemens Healthineers, Oost NL, University Radiology Group, SHIFT Invest
PartnershipsNetherlands Cancer Institute (NKI-AVL), Memorial Sloan Kettering (MSKCC), Radboudumc (RUMC) (aiEMBRACE project), Ferrum Health, Microsoft for Healthcare (Precision Imaging Network), RAYUS Radiology, Aidoc, Fujifilm, Densitas
AcquisitionsBiomediq A/S (January 2025)
TechnologyDeep learning, AI-driven image analysis, Transpara (flagship product), fusion AI for 2D and 3D mammography, cloud-native (via Microsoft Precision Imaging Network), integrates with PACS and AI platforms
FDA Clearances2+ cleared products (estimated)

What Physicians Need to Know

AI-Driven Medical Image Analysis
ScreenPoint Medical specializes in AI-powered analysis of mammograms and digital breast tomosynthesis (DBT) to identify suspicious regions and assess the likelihood of malignancy. Their flagship product, Transpara, provides decision support for both 2D and 3D mammography.
Mammography & Breast Cancer Detection
Transpara is considered a gold standard in AI breast cancer detection, clinically proven to increase cancer detection by 29% while reducing radiologist workload by 44% in randomized controlled trials like the MASAI study.
Early Detection & Decision Support
The technology aids in earlier cancer detection by providing a 'second pair of eyes' to radiologists, enhancing their ability to find more cancers. It offers decision support by categorizing exams based on breast cancer risk (Elevated, Intermediate, Low) and highlighting areas of suspicion.
Breast Density & Risk Assessment
Transpara Density provides both BI-RADS-like assessments and volumetric breast density measurements for consistent analysis and reporting. The company also offers image-based breast cancer risk algorithms for 5-year risk prediction.
Workflow Optimization
Transpara streamlines radiologists' reviews, prioritizes high-risk cases, and significantly reduces reading workload without compromising clinical quality. Studies show it can save up to 44% of workload in a double-reading environment.
Physician Tip

For physicians, ScreenPoint Medical's Transpara offers a powerful AI assistant that enhances diagnostic accuracy and efficiency. Its robust clinical validation, including the first and only randomized controlled trial in Breast AI, provides a high level of confidence in its performance. The system's ability to triage cases by risk and highlight suspicious areas allows for focused attention on critical exams, potentially reducing burnout and improving overall workflow. Furthermore, its consistent performance across diverse patient demographics and breast densities ensures reliable support in varied clinical settings. The seamless integration capabilities mean minimal disruption to existing PACS and reading environments. This translates to earlier detection of breast cancers, improved patient outcomes, and a more streamlined, confident reading experience for radiologists.

ScreenPoint Medical's Transpara is designed for flexible and native integration across diverse imaging infrastructures and enterprise healthcare systems. It collaborates with leading PACS providers, AI platforms, and imaging technology partners (e.g., Microsoft's Precision Imaging Network, Ikonopedia) to ensure seamless deployment within existing clinical workflows without disruption. This vendor-agnostic approach supports efficient, AI-enhanced breast cancer screening regardless of the acquisition type (FFDM, DBT) or reading environment.

Products by ScreenPoint Medical B.V.

3 products in the directory

ScreenPoint Medical
ScreenPoint Medical
Clinical Decision Support & Reference
ScreenPoint Medical offers Transpara, an AI-powered solution for breast cancer detection and diagnosis in mammography and digital breast tomosynthesis, designed to assist radiologists.
Transpara Density
Screenpoint Medical B.V.
Oncology AI
Transpara Density is an AI-powered software that automates breast density assessment, providing BI-RADS-like and volumetric breast density (VBD) measurements for consistent and compliant reporting in mammography.
Transpara
ScreenPoint Medical B.V.
Clinical Decision Support & Reference
Transpara is an FDA-cleared AI solution by ScreenPoint Medical B.V. that enhances breast cancer detection and optimizes radiologist workflow for 2D and 3D mammography.

What the Web Says

ScreenPoint Medical B.V. generally receives positive feedback, particularly for its AI-powered mammography solutions like Transpara. Users highlight its effectiveness in improving diagnostic accuracy and workflow efficiency. Employer reviews, though less numerous, also lean positive, emphasizing a good work environment and innovative focus.

Overall: Positive

Strengths

  • Improved accuracy in mammography readings with AI assistance
  • Enhances workflow efficiency for radiologists
  • User-friendly interface and integration with existing systems (Transpara)
  • Strong scientific backing and continuous innovation
  • Positive impact on patient care through earlier detection
  • Good work-life balance and supportive culture (employer reviews)

Limitations

  • Initial setup and integration can be complex for some institutions
  • Cost may be a barrier for smaller practices or those with limited budgets
  • Reliance on AI may lead to over-reliance if not used judiciously
  • Limited number of employer reviews available for a comprehensive view
  • Specific feature requests or minor bugs occasionally mentioned
  • Training curve for new users to fully leverage all features

Based on reviews from: G2, Glassdoor, Capterra, Healthcare IT News, Radiology Business, AuntMinnie.com, Reddit

Last updated: 2026-07-17

Videos

News, demos, and interviews about ScreenPoint Medical B.V..

Loading videos...

Videos load interactively. If none appear, search YouTube for ScreenPoint Medical B.V. →

View all on YouTube

Press & Coverage

ScreenPoint Medical (via PRNewswire)
ScreenPoint Medical Secures $16M to Lead the Next Phase of AI in Breast Cancer Care
ScreenPoint Medical announced $16 million in new funding from existing investors Insight Partners and Siemens Healthineers, along with research grants, to advance its AI solutions for breast cancer detection and risk assessment. The funding follows groundbreaking research, including the MASAI trial published in The Lancet, demonstrating favorable outcomes for their Transparau00ae Breast AI solutions.
2026-04
AuntMinnie
ScreenPoint Medical raises $16M for breast AI expansion
ScreenPoint Medical secured $16 million in funding from Insight Partners and Siemens Healthineers, plus research grants, to support product development and international expansion of its Transpara breast AI solutions. This announcement coincides with recent research milestones, including positive results from the MASAI trial published in The Lancet.
2026-04
ScreenPoint Medical (via PRNewswire)
The Lancet publishes final results from the first randomized controlled trial in Breast AI
ScreenPoint Medical highlighted new research from the MASAI randomized controlled trial, published in The Lancet, showing that Transpara Detection contributed to a 12% reduction in interval cancers and 27% fewer aggressive cancers. Previous research from 2023 and 2025 indicated a 29% increase in cancer detection and a 44% reduction in screen-reading workload.
2026-01
PR Newswire
ScreenPoint Medical and Ferrum Health partner to offer Transpara Breast AI through Ferrum's AI Governance Suite
ScreenPoint Medical announced a partnership with Ferrum Health to make its Transpara Breast AI Suite available on Ferrum Health's Model Hub. This collaboration aims to provide healthcare organizations with a unified platform for deploying, managing, and measuring AI solutions in breast imaging.
2026-01
ScreenPoint Medical
ScreenPoint Medical Acquires Biomediq A/S to Expand Breast Cancer Risk Assessment Capabilities
ScreenPoint Medical acquired Biomediq A/S, a company specializing in quantitative imaging biomarkers, to integrate breast cancer risk assessment capabilities into its Transpara Breast AI. This acquisition follows a decade of collaboration and aims to enhance Transpara's ability to analyze future breast cancer risk using 2D and 3D mammograms.
2025-01
PR Newswire
Transparau00ae Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
ScreenPoint Medical's Transpara breast imaging AI solution was chosen for the PRISM (Pragmatic Randomized Trial of Artificial Intelligence for Screening Mammography) Trial, a $16 million randomized controlled trial funded by PCORI. This trial is the first large-scale study in the United States to evaluate the role of AI in breast cancer screening.
2025-09
ScreenPoint Medical
ScreenPoint Medical highlights Transpara regulatory clearances
ScreenPoint Medical has achieved regulatory clearance for its algorithms in 40 countries, including FDA clearance (K241831 and K232096) and CE (0344) certification. Transpara Detection can be used as decision support, an independent second reader, or a workflow optimization tool.
2025-10
Lancet Digital Health
AI as an independent second reader in detection of clinically relevant breast cancers within a population-based screening programme in the Netherlands: a retrospective cohort study
A retrospective cohort study in the Netherlands found that combining single human reading with AI (Transpara) improved sensitivity by 8.4% in detecting clinically relevant breast cancers compared to double human reading. The study, published in Lancet Digital Health, analyzed over 40,000 mammograms.
2025-08

Frequently Asked Questions

ScreenPoint Medical offers the Transpara Breast AI Suite, which includes Transpara Detection for identifying suspicious regions and assessing malignancy likelihood in 2D and 3D mammograms, and Transpara Density for automated BI-RADS-like and volumetric breast density assessment. Additionally, Transpara provides Temporal Comparison capabilities to track findings across multiple prior mammograms, enhancing early detection and decision support.
Transpara Breast AI is designed to act as a concurrent reading aid, helping radiologists streamline reviews, prioritize high-risk cases, and potentially reduce workload by up to 44% while increasing cancer detection by 29%. It categorizes exams into risk levels (Elevated, Intermediate, Low), allowing for expedited review of low-risk cases which have a 99.97% negative predictive value.
ScreenPoint Medical's Transpara Density provides both BI-RADS-like and volumetric breast density assessments, aiding compliance with regulations like the MQSA Final Rule. The company has also expanded its breast cancer risk assessment capabilities through the acquisition of Biomediq A/S, combining lesion detection, volumetric density, and mammographic texture analysis to predict future breast cancer risk.
Transpara Breast AI is FDA cleared and CE marked for both 2D and 3D mammography, demonstrating adherence to international standards. It is designed for vendor-agnostic and seamless integration with existing PACS systems, AI platforms, and imaging technologies, ensuring it fits efficiently into current clinical workflows without disruption.
ScreenPoint Medical, founded in 2014, demonstrates strong company stability with significant funding rounds, including $14 million in new funding in 2026 from existing investors like Insight Partners and Siemens Healthineers. They have strategic partnerships with major players such as Siemens Healthineers, Ferrum Health, Ikonopedia, Aidoc, and Microsoft for Healthcare, and offer dedicated customer support via email and phone across different regions.
Yes, Transpara Detection has regulatory clearance in some regions, including CE marking, to be used as decision support, an independent second reader, or a tool to optimize workflow. Studies, such as the MASAI randomized controlled trial, have shown that Transpara-assisted workflows can improve cancer detection and reduce radiologist workload, supporting its role in evolving screening paradigms.

Related Companies

e4health is a healthcare consulting and services company that provides innovative solutions to hospitals, health systems, outpatient providers, and physician practices. The company focuses on addressing data, quality, and revenue challenges within the healthcare ecosystem. Their services are designed to streamline health information data and workflows, optimize coding, quality, and clinical documentation integrity processes, and […]

PayZen is a healthcare AI company dedicated to solving the healthcare affordability crisis for both patients and providers. The company’s AI-powered platform offers personalized, interest-free, and fee-free patient financing solutions, enabling patients to manage their medical bills through affordable payment plans tailored to their unique ability to pay. This approach aims to increase access to […]

Healthcare Finance.AI is a company dedicated to leveraging cutting-edge artificial intelligence to optimize healthcare revenue cycles. Their goal is to improve financial outcomes for healthcare providers while simultaneously supporting the industry’s commitment to quality care and efficiency. They aim to achieve this by enhancing healthcare finance through AI innovation, demonstrating increased revenue cycle efficiency, reducing […]

The American Academy of Family Physicians (AAFP) is one of the largest national medical organizations in the United States, representing over 130,000 family physicians, residents, and medical students. Founded in 1947, its core mission is to improve the health of patients, families, and communities by serving the needs of its members with professionalism and creativity. […]

Imperial College Business School is a global business school that is part of Imperial College London, a top-ranking science-based institution. Established in 2004, the school integrates business and entrepreneurship with technology. Its roots in business education trace back to 1955 with an operational research/management science course. The school is triple-crown accredited (AACSB, AMBA, EQUIS), placing […]

Columbia University, through its online learning initiative ColumbiaX on edX, offers a range of courses, including those focused on healthcare AI. The university is a global leader in research, teaching, and public impact, consistently ranked among top universities. Their online offerings reflect a commitment to academic excellence and expanding access to high-quality education worldwide. For […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.